Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Epstein-Barr Viral Infections - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Epstein-Barr Viral Infections - Pipeline Review, H1 2016', provides an overview of the Epstein-Barr Viral Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Epstein-Barr Viral Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epstein-Barr Viral Infections and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Epstein-Barr Viral Infections - The report reviews pipeline therapeutics for Epstein-Barr Viral Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Epstein-Barr Viral Infections therapeutics and enlists all their major and minor projects - The report assesses Epstein-Barr Viral Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Epstein-Barr Viral Infections Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Epstein-Barr Viral Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Epstein-Barr Viral Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Epstein-Barr Viral Infections Overview 8 Therapeutics Development 9 Pipeline Products for Epstein-Barr Viral Infections - Overview 9 Pipeline Products for Epstein-Barr Viral Infections - Comparative Analysis 10 Epstein-Barr Viral Infections - Therapeutics under Development by Companies 11 Epstein-Barr Viral Infections - Therapeutics under Investigation by Universities/Institutes 12 Epstein-Barr Viral Infections - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Epstein-Barr Viral Infections - Products under Development by Companies 16 Epstein-Barr Viral Infections - Products under Investigation by Universities/Institutes 17 Epstein-Barr Viral Infections - Companies Involved in Therapeutics Development 18 Arno Therapeutics, Inc. 18 Cell Medica Limited 19 Epiphany Biosciences, Inc. 20 Genocea Biosciences, Inc. 21 Molplex Ltd. 22 Savoy Pharmaceuticals, Inc. 23 Theravectys SA 24 ViroStatics, srl 25 Epstein-Barr Viral Infections - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 AR-12 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Cellular Immunotherapy for EBV Associated PTLD - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Cellular Immunotherapy for Infectious Disease - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Cellular Immunotherapy for Infectious Diseases - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Cellular Immunotherapy for Systemic Lupus Erythematosus and Epstein-Barr Viral Infections - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Cellular Immunotherapy for Viral Infections - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Cellular Immunotherapy to Target Calcineurin A for EBV associated post transplant B cell lymphoma - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 CMD-003 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Epstein-Barr virus (virus like particle) vaccine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Epstein-Barr virus (virus like particle) vaccine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Epstein-Barr virus vaccine - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 MVA vaccine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Small Molecule for Infectious Mononucleosis - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Small Molecule to Inhibit EBNA1 for Epstein-Barr Virus (EBV) Infections - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Small Molecules to Inhibit EBNA1 for EBV Latent Infection - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Vaccine for Epstein-Barr Virus and Oncology - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 valomaciclovir stearate - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Viroprev - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Epstein-Barr Viral Infections - Recent Pipeline Updates 61 Epstein-Barr Viral Infections - Dormant Projects 64 Epstein-Barr Viral Infections - Product Development Milestones 65 Featured News & Press Releases 65 Mar 25, 2014: University of Birmingham launches trial to fight cancer caused by a common virus 65 Nov 08, 2011: Protection against Epstein-Barr virus: new approach towards an effective vaccine 65 Appendix 67 Methodology 67 Coverage 67 Secondary Research 67 Primary Research 67 Expert Panel Validation 67 Contact Us 67 Disclaimer 68
List of Tables Number of Products under Development for Epstein-Barr Viral Infections, H1 2016 9 Number of Products under Development for Epstein-Barr Viral Infections - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Epstein-Barr Viral Infections - Pipeline by Arno Therapeutics, Inc., H1 2016 18 Epstein-Barr Viral Infections - Pipeline by Cell Medica Limited, H1 2016 19 Epstein-Barr Viral Infections - Pipeline by Epiphany Biosciences, Inc., H1 2016 20 Epstein-Barr Viral Infections - Pipeline by Genocea Biosciences, Inc., H1 2016 21 Epstein-Barr Viral Infections - Pipeline by Molplex Ltd., H1 2016 22 Epstein-Barr Viral Infections - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016 23 Epstein-Barr Viral Infections - Pipeline by Theravectys SA, H1 2016 24 Epstein-Barr Viral Infections - Pipeline by ViroStatics, srl, H1 2016 25 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Stage and Target, H1 2016 28 Number of Products by Stage and Mechanism of Action, H1 2016 30 Number of Products by Stage and Route of Administration, H1 2016 32 Number of Products by Stage and Molecule Type, H1 2016 34 Epstein-Barr Viral Infections Therapeutics - Recent Pipeline Updates, H1 2016 61 Epstein-Barr Viral Infections - Dormant Projects, H1 2016 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
